,,ii  #aahth ,,congress  #ast ,session  
,s4 #ebf  ,,in ,,the ,,senate ,,of ,,the
 ,,united ,,states  ,february #af1      
#bjbc,mr4 ,wicker 7for himself and ,ms4 
,klobuchar7 introduced the following    
bill2 which was read twice and referred 
to the ,committee on ,health1           
,education1 ,labor1 and ,pensions  ,a   
,,bill  ,to strengthen the use of       
patient-experience data within the      
benefit-risk framework for approval of  
new drugs4  #a4 ,short title ,this ,act 
may be cited as the ,better ,empowerment
 ,now to ,enhance ,framework and        
,improve ,treatments ,act of #bjbc or   
the ,,benefit ,act of #bjbc4  #b4       
,strengthening the use of               
patient-experience data within          
risk-benefit framework ,section #efi;,c 
of the ,federal ,food1 ,drug1 and       
,cosmetic ,act 7#ba ,u4,s4,c4           
#cfj;bbb-#h;c7 is amended-- 7#a7 in     
subsection 7a77#a7-- 7,a7 in            
subparagraph 7,a71 by striking 2 and and
 inserting a semicolon2  7,b7 in        

subparagraph 7,b71 by striking the      
period and inserting 2 and2 and  7,c7 by
 adding at the end the following3  7,c7 
as part of the risk-benefit assessment  
framework in the new drug approval      
process described in section #eje7;d71  
considering patient experience data     
submitted by the medical product sponsor
 or another party4  2 and  7#b7 in      
subsection 7b77#a71 by inserting 1      
including a description of how such data
 and information were considered in the 
risk-benefit assessment described in    
section #eje7;d7 before the period at   
the end4